Systemic Lupus Erythematosus Internist Update Khaled Al Jarallah ,MD FRCPC,FACP,FACR Internist, Rheumatologist Medical Department Faculty of Medicine Kuwait University No disclosures related to the presentation Learning objectives • To highlight the natural history of SLE • To develop a clinical approach to patient suspected to have SLE • To define your therapeutic strategies to each SLE patient based upon activity, severity, organ damage, and comorbidities Multi-Systemic Autoimmune Disease Heterogeneous disease Lupus patient mind map ! Aetiology ? Genetics Hormonal Environmental Genetics Moser K et al, Genes and Immunity 2009 Genetics Criswell LA et al. The Rheumatologist 2011. Environmental • • • • • Ultraviolet light Drugs Infection Smoking Silica dust Pathogenesis Innate Adaptive Ann Rheum Dis 2010;69:1603–11 Pathogenesis www.dressage-de-chien.net Natural history of SLE Ann Rheum Dis 2010;69:1603–11 The 4 D’s clinical approach • Diagnostic workup • Disease activity assessment • Damage assessment • Design treatment goals Diagnostic workup • No gold standard test • Clinical reasoning • Classification criteria Diagnostic workup • Identify disease manifestations • Perform Lab. Tests • Exclude other diseases • Distinguish activity from chronicity • Prioritize active disease manifestations SLE target Which one is lupus rash ? A B C Lupus mimickers Dermatological conditions: Rosocea, dermatitis Chronic autoimmune disorders: sjogrens, MCTD , JIA Vasculitis either primary or secondary to infection (Hep C, parvovirus B19 ,HIV, EB virus) or malignancy Kikuchi-Fujimoto disease Multiple Sclerosis Case presentation • A 25-year-old woman. Her disease manifestations consists of : • Fatigue • Hemolytic anemia • ANA + • Anti-Sm + • C3,C4,CH50 Low Classification criteria for SLE Year 1971 American College of Rheumatology (ACR) classification Criteria for SLE classification developed 1982 1997 Revised classification Revised again 2012 SLICC SLE Criteria 1971 ACR criteria for classification of SLE Clinical Criteria 1 Facial erythema 2 Discoid lupus 3 Clinical Criteria 9 Chronic false positive seologic test for syphilis Raynaud's phenomenon 10 Proteinuria (>3.5 gm/day) 4 Alopecia 11 Cellular casts 5 Photosensitivity 12 Pleuritis or pericarditis 6 Oral or nasal ulcers 13 Psychosis or convulsions 7 Arthritis without deformity 14 8 L.E cells (2 or more) Hemolytic anemia or Leukocytopenia (<4,000 /m) or Thrombocytopenia (<100,000 /m) Any of four or more criteria should be present , serially or simultaneously 1982 revised classification criteria Clinical Criteria 1 Malar Rash 2 Discoid Rash 3 Photosensitivity 4 Oral ulcers 5 Arthritis 6 Serositis 7 Renal Disorder 8 Neurologic Disorder 9 Hematologic disorder 10 Immunologic disorder 11 Antinuclear Antibody Any of four or more criteria should be present , serially or simultaneously 1997 Revised classification criteria Clinical Criteria Immunologic disorder 1 Malar Rash a) Anti-DNA or 2 Discoid Rash b) Anti- Sm or 3 Photosensitivity 4 Oral ulcers 5 Arthritis c) Positive finding of antiphospholipid antibodies based on: 6 Serositis 7 Renal Disorder 8 Neurologic Disorder 9 Hematologic disorder 10 Immunologic disorder 11 Antinuclear Antibody 1.Abnormal IgG/ IgM anticardiolipin antibodies 2. Positive Lupus anticoagulant 3. False positive seologic test for syphilis for 6 months Any of four or more criteria should be present , serially or simultaneously 2012-SLICC* classification criteria At least 1 clinical + at least 1 immunologic Criteria ( for a total of 4) OR Lupus Nephritis by biopsy with ANA or anti-dsDNA antibodies * Systemic Lupus International Collaborating Clinics Petri M et al. Arthritis Rheum 2012;64(8):2677-86 2012-SLICC classification criteria Clinical Criteria 1 Acute Cutaneous Lupus 2 Chronic Cutaneous Lupus 3 Oral or nasal ulcers 4 Non-scarring alopecia 5 Arthritis 6 Serositis 7 Renal Disorder 8 Neurologic Disorder 9 Hemolytic anemia 10 Leukopenia/ Lymphopenia 11 Thrombocytopenia Lupus specific Histopathologic findings of interface dermatitis Acute Cutaneous / Subacute Cutaneous Lupus • • • • • • • Malar rash Bullous lupus Toxic epidermal necrolysis Maculopapular lupus rash Photosensitive lupus rash Nonindurated psoriasiform Annular polycyclic rash Chronic Cutaneous Lupus • • • • • • • Discoid rash, localized & generalized Hypertrophic ( verrucous ) lupus Lupus panniculitis ( profundus ) Lupus erythematosus tumidis Chilblains lupus Mucosal lupus Lichen planus overlap SLE- Cutaneous manifestations 2012-SLICC classification criteria Clinical Criteria 1 Acute Cutaneous Lupus 2 Chronic Cutaneous Lupus 3 Oral or nasal ulcers 4 Non-scarring alopecia 5 Arthritis 6 Serositis 7 Renal Disorder 8 Neurologic Disorder 9 Hemolytic anemia 10 Leukopenia/ Lymphopenia 11 Thrombocytopenia 2012-SLICC classification criteria Immunologic Criteria 1 ANA 2 Anti-DNA 3 Anti- Sm 4 Antiphospholipid antibodies Lupus anticoagulant False+ rapid plasma reagin Anticardiolipin , IgA, IgG or IgM Anti-B2-glycoprotein I ,IgA, IgG or IgM 5 Low complements (C3,C4 or CH 50) 6 Direct Coombs test ( in absence of hemolytic anemia) Performance of the classifications as compared to the current ACR criteria on the sample based on 702 cases* Rule ‘Sensitivity’ ‘Specificity’ Misclassified cases (n) 1997 ACR criteria 267/310 (86%) 365/392 (93%) 70 SLICC criteria 292/310 (94%) 361/392 (92%) 49 *Petri M et al. Arthritis Rheum. 2012;64(8): 2677 Case presentation • A 25-year-old woman. Her disease manifestations consists of : • Fatigue • Hemolytic anemia • ANA + • Anti-Sm + • C3,C4,CH50 Low Cumulative SLE features in different ethnic groups #European N=1000 $Filipino N=1,070 India* N=1366 Kuwait**, Saudi@ N=732 Malar Rash 58 49 58 49 Discoid Rash 10 26 7 15 Photosensitivity 45 33 48 38 Oral ulcers 24 33 55 27 Arthritis 87 68 85 89 Serositis 29 12 22 41 Renal Disorder 37 47 73 49 Neurologic Disorder 23 13 51 24 Hematologic disorder 53 37 26 64 Immunologic disorder Anti-DNA Anti- Sm VDRL 58 13 6 - 68 29 8 74 25 9 Antinuclear Antibody 94 - 98 96 *Lupus 1997; **1998; @2009; $Mod Rheumatol 2008; #Medicine (Baltimore) 1993 Cumulative frequencies of SLE features Manifestation Frequency Constitutional symptoms 90%-95% Mucocutaneous involvement Musculoskeletal involvement Serositis Glomerulonephritis Neuropsychiatric involvement Autoimmune cytopenia 80%-90% 80%-90% 50%-70% 40%-60% 40%-60% 20%-30% Vitali C et al.Clin Exp Rheumatol 1992 The 4 D’s clinical approach • Diagnostic workup • Disease activity assessment • Damage assessment • Design treatment goals Disease activity assessment • Which instrument to choose? • SLEDAI ,BILAG ,SLAM, ECLAM, SRI • Activity, severity, reversibility SELENA-SLEDAI SLEDAI • Evaluates 24 lupus manifestations • Parameters are scored √ if present • Manifestation items are weighted with scores ranging from 1 to 8 • Scores are totaled – Mild: 0-5 – Moderate: 6-12 – Severe: 13-20 Bombardier C et al. Arthritis Rheum. 1992; 35:630-640 SLEDAI SLEDAI Score Yes No Descriptor Definition 8 1 0 Seizure Recent onset. Exclude metabolic, infectious, or drug causes. 8 1 0 Psychosis Altered ability to function in normal activity. Include hallucinations, incoherence , marked loose associations, marked illogical thinking, bizarre, disorganized, or catatonic behavior. 8 1 0 Organic brain syndrome Altered mental function with impaired orientation, memory, or other intellectual function, rapid onset and fluctuating clinical features 8 1 0 Visual disturbance Retinal changes of SLE. Include cytoid bodies, retinal hemorrhages, serous exudate or hemorrhages in the choroid, or optic neuritis. 8 1 0 Cranial nerve disorder New onset of sensory or motor neuropathy involving cranial nerves. 8 1 0 Lupus headache Severe, persistent headache; may be migrainous, but must nonresponsive to narcotic analgesia. 8 1 0 CVA New onset of cerebrovascular accident(s). Exclude arteriosclerosis. 8 1 0 Vasculitis Ulceration, gangrene, tender finger nodules, periungual infarction, splinter hemorrhages, or biopsy or angiogram proof of vasculitis. SLEDAI SLEDAI Score Yes No Descriptor Definition 4 1 0 Arthritis More than 2 joints with pain and signs of inflammation 4 1 0 Myositis Proximal muscle aching/weakness, associated with elevated CPK/ aldolase /EMG changes /biopsy showing myositis 4 1 0 Urinary casts Heme-granular or red blood cell casts 4 1 0 Hematuria >5 red blood cells/high power field. Exclude stone, infection, others 4 1 0 Proteinuria >0.5 gm/24 hours. 4 1 0 Pyuria > 5 white blood cells/high power field. Exclude infection. 2 1 0 Rash Inflammatory type rash. 2 1 0 Alopecia Abnormal, patchy or diffuse loss of hair. 2 1 0 Mucosal ulcers Oral or nasal ulcerations 2 1 0 Pleurisy Pleuritic chest pain with pleural rub or effusion, or pleural thickening. 2 1 0 Pericarditis Pericardial pain with at least 1 of the following: rub, effusion, or +ECG or echo 2 1 0 Low complement Decrease in CH50. C3. or C4 below the lower limit of normal for testing laboratory. 2 1 0 Increased DNA binding Increased DNA binding above normal range for testing laboratory. 1 1 0 Fever >38°C. Exclude infectious cause. 1 1 0 Thrombocytopenia < 100x109 platelets/L. Exclude drug causes 1 1 0 Leukopenia < 3x109 WBC/L. Exclude drug causes The 4 D’s clinical approach • Diagnostic workup • Disease activity assessment • Damage assessment • Design treatment goals Damage assessment • Which instrument to choose? • SLICC/ACR damage index • Chronicity, damage, irreversibility SLICC/ACR damage Index • Validated & used in clinical trails • Records damage in 12 organs or systems • The damage must present in the last 6 month • High damage index correlate with poor prognosis SLICC/ACR damage Index Item Score Ocular • Any cataract ever • Retinal change or optic atrophy 0,1 0,1 Neuropsychiatric • Cognitive impairment/ major psychosis • Seizures requiring therapy for 6 months • CVA ever (score 2 if >1) • Cranial or peripheral neuropathy • Transverse myelitis 0,1 0,1 0,1 0,1 0,1 Renal • Estimated GFR <50% • Proteinuria >3.5 gm/24 h • ESRD 0,1 0,1 3 Pulmonary • Pulmonary hypertension • Pulmonary fibrosis and radiograph) • Shrinking lung (radiograph) • Pleural fibrosis (radiograph) • Pulmonary infarction (radiograph) 0,1 0,1 0,1 0,1 0,1 Cardiovascular • Angina or coronary artery bypass • Myocardial infarction ever (score 2 if > 1) • Cardiomyopathy (ventricular dysfunction) • Valvular disease (murmur >3/6) • Pericarditis for 6 months, or pericardiectomy 0,1 0,1,2 0,1 0,1 0,1 Item Score Peripheral vascular • Claudication for 6 months • Minor tissue loss (pulp space) • Significant tissue loss ever ( loss of digit) (score 2 if >1 site) • Venous thrombosis, swelling, ulceration, or venous stasis 0,1 0,1,2 0,1 0,1 Gastrointestinal • Infarction or resection of bowel below duodenum spleen, liver, or gall bladder ever, for cause any (score 2 if > 1 site) • Mesenteric insufficiency • Chronic peritonitis • Stricture or upper gastrointestinal tract surgery ever 0,1 0,1,2 0,1 0,1 Musculoskeletal • Muscle atrophy or weakness • Deforming or erosive arthritis • Osteoporosis with fracture or vertebral collapse • Avascular necrosis (score 2 if >1) • Osteomyelitis • Tendon Rupture 0,1 0,1 0,1 0,1,2 0,1 0,1 Skin • Scarring chronic alopecia • Extensive scarring other than scalp and pulp space • Skin ulceration (excluding thrombosis) for >6 months 0,1 0,1 0,1 Premature gonadal failure 0,1 Diabetes (regardless of treatment) 0,1 Malignancy (exclude dysplasia) (score 2 if > 1 site) 0,1,2 Damage (nonreversible change, not related to active inflammation) occurring since onset of lupus, ascertained by clinical assessment and present for at least 6 months unless otherwise stated. Repeat episodes must occur at least 6 months apart to score 2. The same lesion cannot be scored twice. SLE Disease assessment Disease Activity SLEDAI Disease Damage SLICC/ACR Damage Index Health Status Assessment SF-36 The 4 D’s clinical approach • Diagnostic workup • Disease activity assessment • Damage assessment • Design treatment goals Design treatment goals • Do good Control disease activity Prevent organ damage Prevent flares • Do no harm Safety profile Drugs Drugs related damage Mortality and Treatment 1950-1954 Corticosteroids 5 year survival , 50% 1940-1950 Antimalarials 1970-1990s Methotrexate Organ transplantation Plasmapheresis Cyclosporine 10 year survival >80% 1960-1970s Cyclophosphamide Azathioprine ‘dialysis’ 10 year survival >60% 2011 Belimumab 2000-2010s Mycophenolate mofetil Biologics , Retuximab Improvement in antibiotic antihypertensive, and antithrombotic therapies Adapted from Manzi S ,ACR 2012 Hydroxychloroquine • • • • • • • • Reduction in flares N Engl J Med 1991;324:150 Reduction in lipids Am J Med 1990;89:322 Reduction in thrombosis Scand J Rheumatol 1996;25:191 Reduction in organ damage Arthritis Rheum 2005;52:1473 Improved survival Lupus 2005;14:220 Triples mycophenolate response Lupus 2006;15:366 Prevents seizure Ann Rheum Dis 2012;71:1502 Reduction in CHB in neonatal lupus Circulation 2012 Vitamin D Improved vitamin D level positively affects: • Disease activity (21% in odds in SLEDAI score 5or>) • Urine protein/Cr (15% in odds in urine pr/cr >0.5) • Systolic blood pressure Low vitamin D is associated with venous thrombosis Petri M et al. ACR abstracts 2012,2013 Overview of management of SLE Establish diagnosis Determine disease activity No major organ involvement • Antimalarials • Low-dose steroids • Azathioprine/methotrexate Assess severity and organ involvement Lifestyle (sun avoidance) Topical agents Symptomatic agents Manage co-morbidities Major organ involvement • Cyclophosphamide (IV) • Mycophenolate mofetil • Calcineurin inhibitors (CyA/tarcolimus ) • Biologics (rituximab/belimumab) or • Enroll in a clinical trial Overview of the management of systemic lupus erythematosus -John A Reynolds, Ian N Bruce Issue 2 (Topical Reviews Series 7) Spring 2013 Treatment targets for SLE Adapted from Xiong W and Lahita RG. Ther Adv Musculoskelet Dis. 2011 Treatment targets for SLE Ryo1m.cocolog-nifty.com Types of Vaccinations Inactivated or killed vaccines Toxoids Live Attenuated Vaccines* Cholera Diphtheria BCG Meningococcal Tetanus Oral Typhoid Pneumococcal Typhoid Hemophilus Influenza B Herpes Zoster Hepatitis A,B Measles, Mumps, Rubella HPV Varicella Polio ( Salk) Polio (oral) Seasonal influenza (IM) Seasonal influenza (Intra nasal) Japanese Encephalitis Yellow Fever Endemic typhus * Not recommended in SLE if on immunosuppressive or biologic medications, low immunoglobulins, hypocomplementemia Conclusions “take home massages” • SLE is a heterogeneous multisystem disease which varies among races and ethnicities • SLE pathogenesis is complex with dysregulation of multiple arms of the immune system • Early lupus diagnosis and disease monitoring remains a challenge for treating physicians • SLICC 2012 revised SLE criteria improved the sensitivity and retained the specificity when compared with 1997 ACR classification Conclusions “take home massages” • Set the treatment goals after Identifying disease manifestations, comorbidities, distinguish activity from chronicity and prioritize active disease manifestations • Use the least toxic medicine and lowest dose to treat the most concerning disease manifestation • Balance the treatment of active disease verses the complications of the treatment Learning Resources • Bertsias GK et al .Diagnostic criteria for Systemic Lupus Erythematosus: has the time come? Nat. Rev. Rheumatol.2013;9: 687-694 • Bertsias GK et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics Ann Rheum Dis 2008;67:195–205 • Hahn BH, et al; American College of Rheumatology. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res . 2012;64:797-808 • www.rheumatolgy.org & www.eular.org Thank you for listening